Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Patient Preference for Oral or Intravenous Vinorelbine in the Treatment of Advanced NSCLC (VIVOS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01848613
Recruitment Status : Completed
First Posted : May 7, 2013
Last Update Posted : November 9, 2018
Sponsor:
Information provided by (Responsible Party):
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori

Brief Summary:

Title: Randomized cross-over study of patient preference for oral or intravenous vinorelbine in the treatment of advanced NSCLC. A phase IV study.

ShortTitle/ Acronym: VIVOS

Protocol Code :IRST162.05

Study Design: Randomized, open label cross-over study

Study Duration: Two years

Study Center(s): Multicenter study

Objectives:

Primary: Patient preference for oral or intravenous vinorelbine Secondary: Overall Response Rate, Time to Progression, Toxicity, Survival, Subjective reasons for treatment choice.

Number of Subjects: 120

Diagnosis and Main Inclusion Criteria:

Patients affected by stage IIIB or stage IV NSCLC candidates to receive a first line chemotherapy with vinorelbine due to age ≥ 70 and Eastern Cooperative Oncology Group (ECOG) Performance status ≤2 or age ≤ 70 but ECOG PS ≥ 2

Study Product, Dose, Route, Regimen and duration of administration :

  • Arm A: first cycle of IV vinorelbine (30 mg/m2) and second cycle of PO vinorelbine (60mg/m2)
  • Arm B: first cycle with PO vinorelbine (60mg/m2) followed by a second cycle of IV vinorelbine (30mg/m2) In both arms vinorelbine will be given at day 1 and day 8 every 3 weeks. From the third cycle onwards patients will have to choose to receive oral or intravenous vinorelbine. Vinorelbine capsules will be administered at the dosage of 60 mg/m2 for the first course and then may be increased to 80 mg/m² at physician's choice.

Treatment will be repeated every 21 days and continued until disease progression, intolerable toxicity or patient refusal.

Reference therapy: Vinorelbine 30 mg/m2 intravenous day 1 and 8 every 21 days

Statistical Methodology: The sample size is calculated based on 75% of patients preferring "oral" vinorelbine and 25% preferring "intravenous" vinorelbine. Therefore, the investigators would compare patients preferring "oral" vinorelbine as 75% compared to a null hypothesis of 50% (no difference in proportion of patients preferring "oral" to "intravenous"). With 80% power and a total alpha of 0.05, the estimated sample size is 60 for group (120 total). During recruitment period, a formal interim analysis was planned when 60 patients (30 for group) have been enrolled, with a p-value <0.0001. To claim statistical significance in the final analysis, the overall p-value is still 5% (referred to Peto-Haybittle rule).


Condition or disease Intervention/treatment Phase
Non-small Cell Lung Cancer Metastatic Drug: Vinorelbine Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 120 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Randomized Cross-over Study of Patient Preference for Oral or Intravenous Vinorelbine in the Treatment of Advanced NSCLC. A Phase IV Study.
Actual Study Start Date : October 2012
Actual Primary Completion Date : October 2016
Actual Study Completion Date : May 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Arm A
•Arm A: first cycle of IV vinorelbine (30 mg/m2) and second cycle of PO vinorelbine (60mg/m2)
Drug: Vinorelbine
Experimental: Arm B
• Arm B: first cycle with PO vinorelbine (60mg/m2) followed by a second cycle of IV vinorelbine (30mg/m2)
Drug: Vinorelbine



Primary Outcome Measures :
  1. Patients preference for IV or PO vinorelbine. [ Time Frame: 2 years ]
    At the time of patient preference, a questionnaire will be filled in by patients.


Secondary Outcome Measures :
  1. Overall response rate (RR) [ Time Frame: 2 years ]
  2. Progression-free survival (PFS) [ Time Frame: 2 years ]
  3. Overall survival (OS) [ Time Frame: 2 years ]
  4. Toxicity of both drug formulations [ Time Frame: 2 years ]
  5. Subjective reasons for treatment choice [ Time Frame: 2 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Histologically or cytologically confirmed stage IIIB or IV NSCLC.
  2. Age ≥ 70 and Eastern Cooperative Oncology Group (ECOG) Performance status ≤2 or age ≤ 70 but ECOG PS ≥ 2
  3. Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >20 mm with conventional techniques or as >10 mm with spiral CT scan. See section 9.2 and Appendix E for the evaluation of measurable disease.
  4. Patients with asymptomatic brain metastases are eligible
  5. Patients with recurrent disease after previous surgery are eligible
  6. Life expectancy > 3 months
  7. Patients must have normal organ and marrow function
  8. Female participants of child bearing potential and male participants whose partner is of child bearing potential must be willing to ensure that they or their partner use effective contraception during the study and for 3 months thereafter
  9. Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

The participant may not enter the study if ANY of the following apply:

  1. Patients who have had previous chemotherapy for lung cancer or radiotherapy on target lesions.
  2. Participation in another clinical trial with any investigational agents within 30 days prior to study screening.
  3. Presence of infection.
  4. Preexisting clinically significant peripheral neuropathy.
  5. History or evidence of malabsorption syndrome or disease that may significantly affect gastrointestinal function.
  6. Patients with known symptomatic uncontrolled brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.
  7. History of allergic reactions attributed to compounds of similar chemical or biologic composition to vinorelbine or other agents used in the study.
  8. Presence of medical problems of sufficient severity to prevent full compliance with the study.
  9. Other known malignant neoplastic diseases in the patient's medical history with a disease-free interval of less than 5 years (except for previously treated basal cell carcinoma and in situ carcinoma of the uterine cervix);

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01848613


Locations
Layout table for location information
Italy
Irccs Irst
Meldola (FC), FC, Italy, 47014
U.O. Oncologia Ospedale Civile degli Infermi
Faenza, RA, Italy, 48018
U.O. Oncologia Ospedale Civile Umberto I
Lugo, RA, Italy, 48022
UO Oncologia Medica, Ospedale S.Maria delle Croci
Ravenna, RA, Italy, 48121
U.O. Oncologia Ospedale Cervesi
Cattolica, RN, Italy, 47841
U.O. Oncologia ed Ematologia Oncologica ULSS 13 MIRANO
Mirano, VE, Italy, 30035
U.O. Oncologia Medica ULSS 1 Belluno
Belluno, Italy, 32100
U.O. Oncologia Ospedale degli Infermi
Rimini, Italy
Sponsors and Collaborators
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Investigators
Layout table for investigator information
Study Chair: Claudio Dazzi, MD UO Oncologia Medica, Ospedale S.Maria delle Croci, RAVENNA - ITALY

Layout table for additonal information
Responsible Party: Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
ClinicalTrials.gov Identifier: NCT01848613     History of Changes
Other Study ID Numbers: IRST162.05
2012-003544-68 ( EudraCT Number )
First Posted: May 7, 2013    Key Record Dates
Last Update Posted: November 9, 2018
Last Verified: November 2018

Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Non-Small-Cell Lung
Carcinoma, Bronchogenic
Bronchial Neoplasms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Vinorelbine
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action